In today’s ACT Brief, we spotlight how new OpenAI collaborations are transforming drug development, how AI is driving smarter site activation in global trials, and how the FDA’s approval of a ...

Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...

On October 27, Thermo Fisher Scientific and Lundbeck both announced new collaborations with OpenAI. These moves represent a continuing trend of drug development companies inking deals with technology ...

In today’s ACT Brief, we examine how artificial intelligence is helping uncover site leaders in underserved regions to strengthen trial diversity—and explore new research suggesting Ozempic may reduce ...